PhRMA Member Companies Raise Concerns With Impact Of Proposed International Pricing Index Model

One of the biggest myths regarding the proposed International Pricing Index Model is that it will have little to no effect on biomedical research and development (R&D). In fact, a recent survey of PhRMA member companies found many expect the proposal to greatly affect their R&D. Download this infographic for some of the key findings from survey respondents.


This website uses cookies and other tracking technologies to optimize performance, preferences, usage, and statistics. By clicking “Accept All”, you consent to store on your device the cookies and other tracking technologies that require consent. You can tailor or change your preferences by clicking “Manage My Cookies”. You can check our privacy policy for more information.